Grant: Operating Grant: Industry-partnered Collaborative Research - Rx&D partner

There are 37 million patients across the world suffering of Alzheimer's disease (AD), the most widespread form of dementia. In the United States, AD affects over 5.3 million individuals and generates cost estimated to 148 billion dollars. Having a life expectancy potentially reaching up to 12 years following diagnosis, degenerating AD patients require constant care and help, and therefore become a demanding responsibility for their families. In Canada, AD affects half a million individuals and this number will more than double within a generation. These statistics imply that AD will have a significant impact on Canadian economy and society. The production of a novel vaccine is therefore a very attracting and inexpensive alternative to prevent and diminish the impact of AD on the Canadian population. In this research program, we will evaluate and select a lead candidate from a family of novel synthetic adjuvants with recently discovered AD-modulating properties to develop a new vaccine to treat AD.